Lineage Cell Therapeutics, Inc. is a Pharmaceuticals company based in the United States of America. With an ESG Risk Rating Score of 26.3, the company is considered to have a medium risk. Lineage Cell Therapeutics is focused on developing and commercializing innovative therapies for degenerative diseases using cell replacement and cell/drug delivery technologies. Their product pipeline includes OpRegen for dry age-related macular degeneration, OPC1 for acute spinal cord injuries, VAC2 for non-small cell lung cancer, ANP1 for hearing loss, and PNC1 for vision loss.